COVID-19: Updates on library services and operations.

Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapies [electronic resource] : workshop summary /
Sharyl J. Nass, Jonathan Phillips, and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National Academies.
Washington, D.C. : The National Academies Press, [2015]
xx, 85 pages : illustrations ; 23 cm
030936857X, 9780309368575
More Details
Washington, D.C. : The National Academies Press, [2015]
Licensed for access by U. of T. users.
contents note
Molecular biology revolution in cancer diagnosis and treatment -- Challenges in biomarker test development -- Regulatory oversight challenges -- Clinical implementation challenges -- Reimbursement challenges -- Gathering the evidence : innovative clinical trials -- Gathering the evidence : coverage decisions -- Gathering the evidence : databases and registries -- Education and clinical decision support needs.
"One of the challenges in treating cancer is the disease's complexity and variation among patients. Cancer manifests differently in each patient, so treatments that are effective in one patient may not be effective in another. As cancer care becomes more personalized, subpopulations of individuals will be given preventive or therapeutic interventions based on their susceptibility to a particular disease or their predicted response to a specific treatment. However, before the use of personalized cancer care can reach its full potential, the health care system must resolve a number of technological, regulatory, and reimbursement issues. To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncology in June 2009. Experts provided presentations on the current state of personalized medicine technology, as well as issues in the validation of, regulation of, and reimbursement for the predictive tests that underpin personalized medicine. Participants discussed the obstacles and possible solutions to further developing and using personalized medicine technologies. This document summarizes the workshop"--
catalogue key
Includes bibliographical references (p. 76-80).

  link to old catalogue

Report a problem